Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
681-700 of 2,251 trials

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Severe Hyponatremia: DDAVP Treatment Study

We are investigating whether DDAVP can help prevent sodium overcorrection in patients with severe hyponatremia. This study aims to improve safety and outcomes for those experiencing dangerously low sodium levels.

Low Sodium Levels (Hyponatremia)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Ulcerative Colitis: Adalimumab Treatment Comparison

We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.

Ulcerative Colitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Pneumonia Prevention: 20-Valent Pneumococcal Vaccine

We are studying whether a new 20-valent pneumococcal vaccine helps prevent pneumonia in adults aged 65 and older. This trial will assess its effectiveness against specific types of pneumonia caused by certain bacteria.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Breast Cancer: Trastuzumab and Pertuzumab Study

We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.

HER2-positive Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Pancreatic Cancer: Testing Enzyme Therapy

We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.

Pancreatic Exocrine Insufficiency6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Zolpidem Responses: Understanding Effects in Different Patients

We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.

Vision ImpairmentsDisorders of ConsciousnessHealthy Volunteers≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurologyPsychiatry

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

Advanced Solid Tumors: TAPISTRY Immuno-Oncology Study

We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.

Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Low Back Pain: PRGF-Endoret® Treatment Study

We are investigating whether PRGF-Endoret® can effectively reduce pain and enhance quality of life in patients with chronic low back pain due to disc degeneration, compared to standard treatments.

Low Back PainMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology